New cell therapy aims to tame painful skin disease
NCT ID NCT06361836
Summary
This early-stage study is testing the safety of SBT777101, a new treatment for hidradenitis suppurativa (HS). The therapy uses a patient's own immune cells, modified to target and calm inflammation in affected skin. Researchers will give single doses to 24 adults with moderate-to-severe HS to see how their bodies react and if the treatment shows any early signs of helping.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
SLUCare Academic Pavillion
St Louis, Missouri, 63110, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.